BLRX three-lens brief
Evidence-based stock research on BLRX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 10.4pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 10.4pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$8.85M).
- Reported earnings on 2026-08-31.
BLRX closed at $2.57 (+0.76%) as of 2026-09-11. Market cap: $11.22M. Price is below the 50-day MA and below the 200-day MA. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 10.4pp over 30 days.. Last quarter: Revenue $477.0K, net income -$1.60M, free cash flow -$8.85M.
Why three lenses on BLRX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BLRXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BLRX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BLRX brief"></iframe>